Meridian Labs Hires Investment Bank to Explore Strategic Opportunities
CHICAGO, Aug. 10, 2012 /PRNewswire-iReach/ — Meridian Labs Inc., a Buffalo Grove, IL -based specialty pharmaceutical company, has appointed AmeriTech Advisors healthcare investment banking team to respond to recent interest from healthcare industry members in making a strategic investment in the company as well as merger and acquisition proposals.
Meridian Labs is a specialty pharmaceutical company focusing on the development of cancer treatments through formulation improvements. The company owns patents on docetaxel and other cancer treatment formulations using the derivatives of beta-cyclodextrin developed through its facilities based in Nanjing, China and Illinois.
The company’s lead product, ML061, is an IP-protected reformulation of Taxotere in Captisol that eliminates Polysorbate 80 and its associated “Black Box” side effects. Meridian intends to gain approval in the US through 5050 (b)(2) submission and will send a pre-IND meeting request to the FDA to on the submission in teh coming weeks. .
Strategic alternatives the Company may pursue could include strategic investment or other collaboration agreements, a merger, an equity or debt financing, or sale of the Company. The Company does not intend to disclose developments with respect to this process until the evaluation of strategic alternatives has been completed and the board of directors has approved a specific transaction.
About Meridian Labs
As the company’s leading product, ML061 improves the formulation of Taxotere for cancer treatment, based on the same active ingredient docetaxel with a novel delivery method. By avoiding polysorbate 80 and ethanol, our objective is to show that ML061 improves the safety profile of Taxotere while maintaining its efficacy. We plan to bring the product to market as the top choice of chemotherapy for various cancer indications.
About AmeriTech Advisors
AmeriTech is an investment bank dedicated to providing capital raising and strategic advisory services to emerging growth companies in the technology and medtech sectors with market capitalizations of between $25 million and $500 million. Their bankers have 20 years’ experience at major global investment banks and as senior managers at public companies with experience executing successful transactions. Their goal is to build mutually beneficial relationships between our emerging growth company clients, technology and medtech/pharma partners, and their network of investors
Media Contact: william zhao, Meridian Lab, 847-275-5923, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Meridian Lab